Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel
Kamada Ltd.January 13, 2021 GMT
The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024
Potential Collective Maximum Sales of the Three Products in the Israeli Market is Estimated at $5-$7 Million Annually
These Sales Are i
n Addition to the Potential $20-$30 Million from the Recently Licensed Alvotech Biosimilar Portfolio
REHOVOT, Israel, Jan. 13, 2021 (GLOBE NEWSWIRE) Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that the Company has entered into agreements with two undisclosed international pharmaceutical companies to commercialize three biosimilar product candidates in Israel. Subject to approval by the European Medicines Agency (EMA) and subsequently by the Israel
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition
Kamada Ltd.January 5, 2021 GMT
REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it has been selected as one of 10 winners of the Genesis Prize Foundation (GPF) Start-Up Nation Central (SNC) competition recognizing Israeli companies working to combat coronavirus and the damage of future pandemics. Based on its development of a plasma derived immunoglobulin (IgG) product as a potential therapy for coronavirus disease (COVID-19), Kamada was selected for its significant contributions towards fighting COVID-19 and advancing a promising technology that has the potential to provide significant benefits in the near future. The winners were announced in a virtual ceremony by Reuven Rivlin, President o